Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 4,718 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clinical Assessment Clear all
Completed Phase 3 Interventional Results available

A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

NCT01275066
View directory record Official record
Conditions
MPS IV A
Interventions
BMN 110 Weekly, Placebo, BMN 110 Every Other Week
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Oakland, California • Wilmington, Delaware • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2014 · Synced Sep 18, 2026, 9:50 AM EDT
Recruiting Not applicable Interventional

Manipulation and Dry Needling in Patients With Cervicogenic Headache and WAD II

NCT06502951
View directory record Official record
Conditions
Cervicogenic Headache, Whiplash Injuries
Interventions
Dry Needling,Thrust Manipulation, Exercise,Non-thrust Mobilization
Other
Lead sponsor
Alabama Physical Therapy & Acupuncture
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Montgomery, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2025 · Synced Sep 18, 2026, 9:50 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

NCT02124902
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Docetaxel, Carboplatin, FDG-PET/MR
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care

NCT02925962
View directory record Official record
Conditions
Hypertension, Renal Insufficiency, Chronic
Interventions
Clinical Decision Support System (CDSS), Clinic Decision Sup System + Pharmacist
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
542 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV-1 DNA Vaccine (VRC HIVDNA009-00-VP) in HIV Uninfected Adults

NCT00071851
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 18, 2026, 9:50 AM EDT
Terminated No phase listed Observational

A Study to Evaluate the Conformis Hip System

NCT03738462
View directory record Official record
Conditions
Clinical Condition Included in the Approved Indications For Use for the Conformis Hip System
Interventions
Conformis Hip System
Device
Lead sponsor
Restor3D
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Timeline
2018 – 2022
U.S. locations
6
States / cities
Roseville, California • Parker, Colorado • Boynton Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Sep 18, 2026, 9:50 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Developing a Clinical Outcome Assessment for Opioid Craving

NCT05109429
View directory record Official record
Conditions
Opioid Craving, Opioid Use Disorder, Measure Development
Interventions
Neutral Cue-induced Craving, Visual Opioid Cue-induced Craving, Visual and Tactile Opioid Cue-induced Craving
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 18, 2026, 9:50 AM EDT
Recruiting Phase 3 Interventional

BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.

NCT07605429
View directory record Official record
Conditions
Angelman Syndrome
Interventions
rugonersen, Sham procedure
Drug · Procedure
Lead sponsor
OHB Pediatrics Ltd.
Industry
Eligibility
1 Year to 50 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Diego, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI)

NCT01324453
View directory record Official record
Conditions
Acute Myocardial Infarction
Interventions
Post Conditioning + Primary PCI, Standard Primary PCI
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Prospective Clinical Trial Designed to Evaluate the Repeatability and Reproducibility of the Intelon BOSS(tm) System

NCT05423041
View directory record Official record
Conditions
Corneal Transplant, Corneal Crosslinking, Healthy Eyes
Interventions
BOSS Imaging
Diagnostic Test
Lead sponsor
Intelon Optics, Inc
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)

NCT04933461
View directory record Official record
Conditions
Accident Injury
Interventions
Safety lancet
Device
Lead sponsor
HTL-Strefa S.A.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 18, 2026, 9:50 AM EDT
Terminated Phase 1 Interventional

Gene Transfer Clinical Study in Crigler-Najjar Syndrome

NCT03223194
View directory record Official record
Conditions
Crigler-Najjar Syndrome
Interventions
AT342
Genetic
Lead sponsor
Audentes Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
The Bronx, New York • Strasburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

NCT00097422
View directory record Official record
Conditions
Diarrhea
Interventions
OPT-80
Drug
Lead sponsor
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New Hope, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

NCT04980495
View directory record Official record
Conditions
Generalized Myasthenia Gravis, MG - Myasthenia Gravis, gMG
Interventions
Efgartigimod IV
Biological
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Carlsbad, California • Orange, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 18, 2026, 9:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results

NCT01384370
View directory record Official record
Conditions
Human Papillomavirus Infection
Interventions
Not listed
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Lake Success, New York • Burlington, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2011 · Synced Sep 18, 2026, 9:50 AM EDT
Terminated Not applicable Interventional

Movement and Fitness Trackers in Determining Performance Status

NCT03971266
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Activity Monitor, Media Intervention
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 18, 2026, 9:50 AM EDT
Completed No phase listed Observational Results available

NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™

NCT02410837
View directory record Official record
Conditions
Lung Lesion(s) Requiring Evaluation
Interventions
Electromagnetic Navigation Bronchoscopy
Procedure
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
1,388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Mountain View, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103
View directory record Official record
Conditions
Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor, Sarcoma, Ewing's, Sarcomas, Epitheliod, Sarcoma, Soft Tissue, Sarcoma, Spindle Cell, Melanoma, Malignant Melanoma, Clinical Oncology, Oncology, Medical, Pediatrics, Osteosarcoma, Osteogenic Sarcoma, Osteosarcoma Tumor, Sarcoma, Osteogenic, Tumors, Cancer, Neoplasia, Neoplasm, Histiocytoma, Fibrosarcoma, Dermatofibrosarcoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Celgene
Industry
Eligibility
6 Months to 24 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)

NCT03633461
View directory record Official record
Conditions
Dry Eye Disease
Interventions
OC-02 (simpinicline) nasal spray, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Louisville, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

NCT02098473
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
RPC4046, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis

NCT03181594
View directory record Official record
Conditions
Chronic Rhinitis
Interventions
ClariFix Device
Device
Lead sponsor
Arrinex, Inc.
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
East Palo Alto, California • Sacramento, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Not applicable Interventional Results available

Augment® Bone Graft (Formerly GEM OS™1 Bone Graft) Compared to Autologous Bone Graft in Foot and Ankle Fusions

NCT00583375
View directory record Official record
Conditions
Foot Fusion
Interventions
Augment® Bone Graft, Standard of Care
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Tucson, Arizona • San Francisco, California • Santa Cruz, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 18, 2026, 9:50 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)

NCT01462292
View directory record Official record
Conditions
Muscular Dystrophies
Interventions
GSK2402968 3mg/kg/week, GSK2402968 6 mg/kg/week, Placebo to match GSK2402968 3 mg/kg/week, Placebo to match GSK2402968 6 mg/kg/week
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
14
States / cities
Sacramento, California • Stanford, California • Gulf Breeze, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2017 · Synced Sep 18, 2026, 9:50 AM EDT